4.6 Article

C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer's disease

期刊

出版社

BMC
DOI: 10.1186/s40478-022-01416-6

关键词

C5aR1; Alzheimer's disease; Microglia; Complement; Neuroinflammation; DAM

资金

  1. NIA [R21 AG061746, R01 AG060148]
  2. Larry L. Hillblom postdoctoral fellowship [2021-A-020-FEL]
  3. Alzheimer's Association Research Fellowship [AARFD-20-677771]
  4. Edythe M. Laudati Memorial Fund
  5. Cancer Center Support Grant at the University of California, Irvine [CA-62203]
  6. Center for Complex Biological Systems Support Grant at the University of California, Irvine [GM-076516]
  7. [T32 AG00096]

向作者/读者索取更多资源

Multiple studies have shown the involvement of the complement cascade in the progression of Alzheimer's disease, but the specific role of C5a-C5aR1 signaling in this neurodegenerative disease is still unclear. However, using the C5aR1 antagonist PMX205 in a mouse model of Alzheimer's disease has shown promising results in reducing neurodegeneration, amyloid load, and synaptic loss, suggesting its potential as a therapeutic target.
Multiple studies have recognized the involvement of the complement cascade during Alzheimer's disease pathogenesis. However, the specific role of C5a-C5aR1 signaling in the progression of this neurodegenerative disease is still not clear. Furthermore, its potential as a therapeutic target to treat AD still remains to be elucidated. Canonically, generation of the anaphylatoxin C5a as the result of complement activation and interaction with its receptor C5aR1 triggers a potent inflammatory response. Previously, genetic ablation of C5aR1 in a mouse model of Alzheimer's disease exerted a protective effect by preventing cognitive deficits. Here, using PMX205, a potent, specific C5aR1 antagonist, in the Tg2576 mouse model of Alzheimer's disease we show a striking reduction in dystrophic neurites in parallel with the reduced amyloid load, rescue of the excessive pre-synaptic loss associated with AD cognitive impairment and the polarization of microglial gene expression towards a DAM-like phenotype that are consistent with the neuroprotective effects seen. These data support the beneficial effect of a pharmacological inhibition of C5aR1 as a promising therapeutic approach to treat Alzheimer's disease. Supportive of the safety of this treatment is the recent FDA-approval of another other C5a receptor 1 antagonist, Avacopan, as a treatment for autoimmune inflammatory diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据